Clinical Trial Update: Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update of a three-drug combination (acalabrutinib, umbralisib, and ublituximab) for previously untreated mantle cell lymphoma; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Ublituximab (ublituximab)
• umbralisib

Snippet

Sponsor: City of Hope Medical Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-18